Loading
A phase 1/2 trial of ASTX660 in non-Hodgkin lymphoma, run by Taiho Oncology, Inc., active and no longer recruiting.
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas is a phase 1/2 interventional study registered as NCT02503423 by Taiho Oncology, Inc., with 253 participants enrolled, started 2015-07-14 and due to reach its primary completion in 2022-10. Interventions recorded: ASTX660.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.